menu
    • menu

    Company profile for Adrenomed

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibodyAdrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity...
    Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibodyAdrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity to treat life-threatening conditions associated with increased vascular leakage, congestion and shock.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AdrenomedGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Neuendorfstraße 15A Hennigsdorf b. Berlin D-16761
    Telephone
    Telephone
    +49 (0) 3302 20 77 8 0
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://adrenomed.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/adrenomed-ag/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/adrenomed

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AdrenoMed Receives FDA Fast Track for Enibarcimab in Septic Shock
    AdrenoMed Receives FDA Fast Track for Enibarcimab in Septic Shock

    10 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/10/2860692/0/en/AdrenoMed-Receives-FDA-Fast-Track-Designation-for-Enibarcimab-for-Treatment-of-Septic-Shock.html

    GLOBENEWSWIRE
    10 Apr 2024
    Share Share
    Adrenomed presents new findings on its precision medicine treatment
    Adrenomed presents new findings on its precision medicine treatment

    08 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/08/2739895/0/en/Adrenomed-presents-new-findings-on-its-precision-medicine-treatment-for-septic-shock-with-enibarcimab-during-Weimar-Sepsis-Update.html

    GLOBENEWSWIRE
    08 Sep 2023
    Share Share
    Adrenomed receives EMA’s advice for clinical development of Adrecizumab
    Adrenomed receives EMA’s advice for clinical development of Adrecizumab

    06 Dec 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=144434&sid=2

    PHARMABIZ
    06 Dec 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search